Columnist Robin Stemple knows that his physical challenges aren't his fault, but that doesn't make it any easier to avoid ...

The investigational drug losmapimod did not significantly change expression of the gene behind facioscapulohumeral muscular dystrophy (FSHD), but it was associated with potential improvements in ...

Please provide your email address to receive an email when new articles are posted on . Treatment with losmapimod and placebo had similar results with respect to primary, secondary endpoints. No ...

Avidity Biosciences said Wednesday morning that an experimental medicine successfully knocked down the gene behind a form of muscular dystrophy being pursued by a fleet of drug companies. The ...

Please provide your email address to receive an email when new articles are posted on . Safety and tolerability of losmapimod were assessed in 108 people with facioscapulohumeral muscular dystrophy.

FSHD Society to host Avidity webinar on positive initial data from the Phase 1/2 FORTITUDE™ trial for people living with FSHD today at 1:00 p.m. ET "This World FSHD Day, we are excited to be joining ...

AOC 1020 on track to be in the clinic by end of 2022 for the treatment of FSHD "We are grateful for our partnership with the global FSHD community as we collectively work together toward developing ...

Facioscapulohumeral muscular dystrophy (FSHD) is the most common of the nine primary types of muscular dystrophy. Studies once estimated prevalence to be about 1 in 20,000 people, according to the FSH ...

VANCOUVER, British Columbia--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization dedicated to catalyzing innovation and overcoming barriers to accelerate new therapies for ...

There are numerous forms of Muscular Dystrophy. For those of us who are affected by it (and for people who don’t know much about the disease) this can be very confusing! I suffer from a particular ...